We are committed to innovation and technological advancement to create new drugs that can help people lead better and more hopeful lives. We are dedicated to the discovery and development of novel, first-in-class antisense drugs to address significant unmet medical needs in a wide variety of diseases. We focus our efforts on developing antisense drugs to treat a broad range of diseases such as cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.
We are dedicated to the pursuit of scientific excellence. With our expertise, our scientists can optimize the properties of our antisense drugs and efficiently screen many targets in parallel to carefully select the best drugs to move into development.
We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions including cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.
If you would like more information about a trial or want to enroll in a trial, please visit www.clinicaltrials.gov. This government-sponsored Web site lists most ongoing trials including those for which enrollment is currently taking place. Information is searchable by company, by drug candidate, by specific indication and by disease area. For each trial, the investigator is named and enrollment information is provided if appropriate.
Information can also be obtained by leaving a message on the following Isis toll-free number: 1-800-679-ISIS (4747) or by visiting our Information Request page and submitting your question online. These latter two channels are most appropriate if you'd like to speak with one of our clinical operations professionals about qualifying as a site or about supplying external services and support for clinical trials.
We know that sick people depend on us, and we have the technology to change the way diseases are treated.Learn More
Our mission is to provide antisense drugs to patients with significant unmet medical needs.Learn More
Isis Pharmaceuticals is currently enrolling a Phase 3 study that is designed to evaluate the safety and efficacy of ISIS-TTRRx in patients with Familial Amyloid Polyneuropathy (FAP), the form of TTR amyloidosis that causes nerve damage.Learn More About the Study